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Abstract: The present study explored sex- and age-related interactions of IGF-I polymorphisms with IGF-I serum levels. 
In 2000 data on IGF-I promoter polymorphism and IGF-I level were available of 344 (mean age 36; 162 men) and 6 years 
later in 287 subjects (133 men). As the sample sizes of groups of subjects with IGF-I genotypes 192/192, 190/192, 
192/194 and 192/196 were large enough to be analyzed, the relationship between these specific genotypes and IGF-I-level 
was determined. The results indicated that in women aged 36 IGF-I levels for genotype 190/192 (mean 29.24 nmol/l) 
were higher than those for genotypes 192/192 (mean 24.29), 192/194 (mean 24.61) and 192/196 (mean 23.93). Male IGF-
I levels were decreased in 2006 compared to 2000 for genotypes 192/192 (mean decline – 3.67), 192/194 (mean decline – 
1.61), 192/196 (mean decline – 4.18), but not for 190/192. Female IGF-I levels were decreased for genotypes 192/192 
(mean decline – 1.85) and 190/192 (mean decline – 4.64), but not for 192/194 and 192/196. Thus females with genotype 
190/192 have higher IGF-I levels, while females with genotypes 192/194 or 192/196 and males with genotype 190/192 do 
not show a decline of IGF-I level.  
Keywords: IGF-I polymorphisms, genotype. 
INTRODUCTION 
 Insulin-like growth factor-I (IGF-I) is a peptide hormone 
that is primarily secreted by the liver and is important for 
growth and development throughout the body. The secretion 
of IGF-I is mainly induced by growth hormone. Other fac-
tors influencing the serum level of IGF-I are nutritional 
status, the serum level of sex steroids and insulin and liver 
function. The level of IGF-I reaches a peak during puberty, 
and declines with age. IGF-I plays an important role in the 
regulation of cell proliferation, differentiation and apoptosis 
and has acute insulin-like metabolic effects [1]. Furthermore, 
IGF-I levels appear to be positively correlated to muscle 
mass, physical condition, the ratio of high-density lipopro-
tein to low-density lipoprotein, bone density, oxygen con-
sumption and overall quality of life, and negatively to body 
fat [2,3]. IGF-I levels have also been shown to have a posi-
tive correlation with cognitive functioning [4]. Low IGF-I 
levels are associated with an increased risk of developing 
cardiovascular disease and diabetes, whereas high IGF-I lev-
els in humans are associated with an increased risk of devel-
oping cancer [5-9].
 
 In addition to the above mentioned factors that can influ-
ence IGF-I levels, it has been estimated that up to 60% of the 
variability has a genetic basis [10,11]. A genetic determinant  
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of the IGF-I level appears to be a polymorphism in the pro-
moter region of the IGF-I gene, being a variable length cyto-
sine-adenine (CA) repeat sequence, which has been investi-
gated in the past years. The repeat lengths found previously 
vary from a minimum of 10 repeats to a maximum of 23 
repeats [6,12]. The term 192 was used to signify the 19 CA 
repeats (192 bp) as reported by Weber and May [13] and 
labeled Z in their initial report. Other polymerase chain reac-
tion (PCR) product sizes ranging from 188–198 were given a 
number designated by the length of the CA repeat [14]. The 
192bp allele and the 194bp allele are the most common al-
leles and therefore considered the wild-types [6,9,15,16]. 
Studies on the IGF-I promoter polymorphism and IGF-I 
level have mainly focused on the 192bp allele. Systematic 
reviews by Fletcher et al. [6] and by Wagner et al. [12] de-
scribe how the influence of the polymorphism on the IGF-I 
level has been investigated in multiple studies, with variable 
outcomes; the first study by Rosen et al.[14] associated the 
192/192 genotype with decreased IGF-1 levels, while subse-
quent studies have shown an association of the 192bp allele 
with increased hormone levels [9,17], with lower IGF-I level 
[18], or have found no association at all [19-22]. Further-
more, Rietveld et al. [23] found that the expected age-related 
decline in IGF-I levels occurred in homozygotes 192/192, 
but not in heterozygotes and non-carriers of the 192bp allele. 
In these studies, groups were generally compared with other 
groups based on the number of 192bp alleles present: homo-
zygotes (192/192) vs. heterozygotes (192/_) vs. non-carriers 
(_/_) or homozygotes vs. heterozygotes and non-carriers 
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combined (192/_ and _/_) or carriers (192/192 and 192/_) vs. 
non-carriers.  
 As the present study is aimed to explore the other geno-
types as well, more specific conclusions concerning differ-
ences in IGF-I levels between genotypes may be drawn.  
 Genetic influence on the IGF-I level is not only interest-
ing because IGF-I levels are associated with certain types of 
cancer, diabetes mellitus and ischemic heart disease [6-9], 
but also because these diseases have been associated with the 
polymorphisms in the IGF-I gene itself, although conclu-
sions have been controversial [6,9,12,24]. The influence of 
the polymorphism on the IGF-I level may be the source of a 
predisposition for these diseases. 
 The aim of this study is to describe the occurrence of 
polymorphisms in the IGF-I gene and genotypes of the dif-
ferent alleles. In addition, the present study explores the rela-
tionship between these genotypes and the IGF-I-level as well 
as the age-related decline of the IGF-I level in a general 
sample of Dutch men and women. 
MATERIALS AND METHODOLOGY 
Subjects 
 The subjects are participants of the Amsterdam Growth 
and Health Longitudinal Study (AGAHLS). In 1976 this 
study was started with a total inclusion of 698 subjects to 
gain an understanding of growth, development and health of 
children in puberty. Data concerning health, lifestyle and 
psychological factors have been collected and data collection 
is still being continued [25]. In 2000 a number of 375 sub-
jects with an average age of 36 years (range 34-38, SD 0.74) 
still participated in the study. A remaining sample of 343 
subjects participated in 2006, at the average age of 42 years 
(range 41-46, SD 0.65). Thus, the present study allows to 
examine IGF-I decline across a 6-year interval. The magni-
tude of IGF-I change per year has been estimated to be 2.1 
ng/ml in men and 2.5 ng/ml in women aged between 40 and 
50 years. The slopes summarizing the age-IGF-I relationship 
for two different studies appeared remarkably similar [26]. 
Although the estimated IGF-I decline of 12.6 ng/ml in males 
and 15 ng/ml in females across 6 years is moderate, the esti-
mation appears to be so precise that this interval may still 
reveal structural differences between genotypes. 
 The distribution of the IGF-I polymorphisms in non-
Caucasian subjects appears to be different than that in Cau-
casian subjects [6,27]. Furthermore, ethnic differences in 
circulating levels of IGF-I have been reported [27,28]. 
Therefore, the 13 subjects with a non-Caucasian ancestry 
were excluded. 
Study Procedure 
 Genetic polymorphisms of the IGF-I-gene and IGF-I lev-
els of 344 Caucasian subjects (162 men, 182 women) were 
determined in 2000 (Table 1). In 287 of these subjects (133 
men, 154 women) a second assessment of IGF-I serum levels 
was done in 2006. 
Genotyping 
 The genetic polymorphisms of the IGF-I-gene were de-
termined as described previously [9]. In brief, DNA was 
isolated using standard methods. PCR was performed in a 
final volume of 10 μL containing 10 ng DNA, 10* Gold 
(Au) buffer (Perkins and Elmer), 200 M dNTP, 30 pmol of 
each primer, 3 mM MgCl2, 0.5 U Ampli Tag Gold polym-
erase (Perkins and Elmer). The PCR program consisted of 30 
cycles of 30 sec 95°C, 30 sec 55°C and 30 sec 72°C and ad-
ditionally 5 min of denaturation at 95°C before the first cycle 
and an extension of 10 min. at 72°C after the last cycle. For-
ward primers were labeled with FAM
12
 to determine the size 
of the PCR products by fragment analysis (ABI-Prism ge-
netic analyzer with Genescan 2.1 software). The Genescan 
350/500 Tamra was used as internal size standard within the 
fragment analysis [16].
 
IGF-I Serum Levels 
 IGF-I serum levels were measured using a commercially 
available assay (Chemiluminescent immunometric, Immulite 
2500, DPC, Los Angeles, USA). The detection limit was 3.2 
nmol/l. The intra and inter assay coefficient of variation were 
both 5% for the entire range. 
Data Analysis 
 First, subjects with missing IGF-I values were removed. 
Then, IGF-I serum levels were compared between geno-
types, sex and year of measurement (2000/2006). Data were 
analyzed using Linear Mixed Model with covariance type 
“unstructured” for repeated measures with Group (genotype) 
and Sex as independent factors and Year as repeated meas-
urements factor [29]. Since it is known that the IGF-I level 
of men generally tends to be higher than that of women, sex 
was also included as independent factor. With respect to 
Group, pairwise comparisons of IGF-I levels in 2000 and 
those in 2006 were made separately for males and females. 
In addition, age-related changes in IGF-I levels were ana-
lyzed with pairwise comparisons of Year (2000/2006) for 
each genotype separately for males and females. All statisti-
cal tests were two-tailed. Significance level was set as alpha 
< 0.05. To control for multiple testing the Benjamini-
Hochberg correction was applied [30]. After the removal of 
subjects with a non-Caucasian ancestry and subjects with 
missing IGF-I values, data from 344 (2000) and 287 (2006) 
subjects were evaluable for the Mixed Linear Models Analy-
sis. Only groups of subjects with genotypes 192/192, 
190/192, 192/194 and 192/196 were found large enough to 
be analyzed taking sex differences into account (n ? 6). The 
other genotypes were analyzed as one remaining group. This 
group consisted of 31 males and 26 females. (males: 176/192 
(n=1), 188/192 (n =7), 188/194 (n = 1), 188/196 (n = 2), 
190/190 (n=1), 190/194 (n = 4), 190/196 (n = 1) 190/198 
(n=1) 192/198 (n=2), 194/194 (n= 3), 194/196 (n = 8); fe-
males: 176/194 (n=1), 176/196 (n=1),188/192 (n=2), 
188/194 (n = 3), 188/196 (n = 1), 190/194 (n = 1), 190/196 
(n = 2), 190/198 (n=1), 192/198 (n=4), 194/194 (n=5), 
194/196 (n = 4), 194/198 (n=1)).  
 All analyses were performed using SPSS (version 16).  
RESULTS 
Genotypes 
 Seven different alleles were present in the study sample. 
The 192bp allele had the highest frequency (63.9%). A num-
ber of 303 subjects (88.1%) were carrier of the 192bp allele. 
Of these carriers, 137 were homozygote for this allele, and 
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166 heterozygote. The 194bp allele was present in 132 sub-
jects (38.4%) of whom 8 were homozygote and 124 were 
heterozygote. The other alleles were found less frequently 
(Table 1). The distribution of genotypes was in Hardy-
Weinberg equilibrium (p = 0.17). 
 Thus, homozygosity for 192bp had the highest preva-
lence and was observed in 137 subjects (39.8%). The com-
bined presence of 192bp and 194bp (192/194) was the  
second most frequently observed genotype, followed by 
192/196, 190/192, and 194/196 genotypes, respectively  
(Table 1). 
Genotypes and IGF-I Level 
 Variation in IGF-I levels has been found to be associated 
with specific lifestyle factors. Particularly, IGF-I concentra-
tions appeared to be inversely related to BMI and the use of 
postmenopausal estrogen formulations [31]. Therefore, with 
respect to our study sample, it is important to note that 
ANOVA separately performed for 2000 and 2006 in males 
and females indicated no difference in BMI between geno-
type groups. In addition, chi-square tests indicated that there 
was no difference in distribution of the use of oral contracep-
tives in 2000 and 2006 across female genotype groups (Ta-
ble 2). 
 Linear Mixed Model Analysis with Group (genotype) 
and Sex as independent factors and Year (2000/2006) as 
repeated measurements factor indicated a significant interac-
tion between Group, Sex and Year (F (4,292) = 2.8, P < 
0.05). 
 To explore the meaning of this interaction, we further 
analyzed differences in IGF-I levels determined in 2000 
separately for males and females and those determined in 
2006 also separately for males and females. Finally, we ana-
lyzed changes in IGF-I levels over time separately for males 
and females. Mean IGF-I levels (nmol/l) ± SD in 2000 and in 
2006 in males and females with different genotypes are 
shown in Table 3. 
IGF-I Levels in 2000 
 With respect to males, pairwise comparisons indicated no 
difference in IGF-I levels in 2000 between genotype groups. 
In contrast, with respect to females, pairwise comparisons 
showed that for females IGF-I levels in the 190/192 group 
(mean = 29.24) were significantly higher than those in the 
192/192 group (mean = 24.29), as well as those in the 
192/194 group (mean = 24.61) as those in the 192/196 group 
(mean = 23.93) (P = 0.006, P = 0.013, and P = 0.014 respec-
tively) (Fig. 1). IGF-I levels of the remaining group (mean = 
28.42) were higher than those of the 192/192 group, as well 
as those of the 192/194 group, as those of the 192/196 group 
(P = 0.002, P = 0.007 and P = 0.012 respectively). All these 
effects were significant after application of the Benjamini-
Hochberg correction for multiple testing (adjusted alpha = 
0.03). 
IGF-I Levels in 2006 
 With respect to IGF-I levels of males in 2006 pairwise 
comparisons indicated that IGF-I levels in the 192/194 group 
(mean = 25.76) tended to be higher than those of the 192/192 
group (mean = 23.17 (P = 0.087). In order to be significant 
after application of the Benjamini-Hochberg correction P 
should be less than the adjusted alpha = 0.005, meaning that 
this finding is likely the result of chance. 
 With respect to females, although the pattern of IGF-I 
levels was similar to that of 2000 pairwise comparisons indi-
cated no difference in IGF-I levels in 2006 between geno-
type groups (Fig. 1). 
IGF-I Level Differences between Age 36 and 42 Years 
 For the whole group of subjects, irrespective of Sex and 
Group, a significant decline in IGF-I levels was seen be-
tween the mean age of 36 and 42 years (P < 0.0001). In addi-
tion, there was no significant interaction between Sex and 
Year, indicating that the decline was similar in males as in 
females.  
 With respect to males, pairwise comparisons indicated 
that after correction with Benjamini-Hochberg (adjusted al-
pha = 0.03) IGF-I levels were decreased in 2006 compared 
to 2000 in subjects with genotypes 192/192 (mean decline – 
3.67 nmol/l, P < 0.0001), 192/194 (mean decline – 1.61 
nmol/l, P = 0.005), 192/196 (mean decline – 4.18 nmol/l P = 
0.02), and were neither decreased in genotype 190/192 nor in 
the remaining group. 
 With respect to females, after correction with Benjamini-
Hochberg (adjusted alpha = 0.03) IGF-I levels were signifi-
cantly decreased in 2006 compared to 2000 in subjects with 
Table 1. Number of Subjects (and Percentages) with Specific 
Genotypes 
Genotype Number of Subjects (%) Men Women 
176/192 1 (0.3) 1 0 
176/194 1 (0.3) 0 1 
176/196 1 (0.3) 0 1 
188/192 9 (2.6) 7 2 
188/194 4 (1.2) 1 3 
188/196 3 (0.9) 2 1 
190/190 1 (0.3) 1 0 
190/192 19 (5.5) 7 12 
190/194 5 (1.4) 4 1 
190/196 3 (0.9) 1 2 
190/198 2 (0.6) 1 1 
192/192 137 (39.8) 62 75 
192/194 101 (29.3) 50 51 
192/196 30 (8.7) 12 18 
192/198 6 (1.7) 2 4 
194/194 8 (2.3) 3 5 
194/196 12 (3.5) 8 4 
194/198 1 (0.3) 0 1 
total 344 (100) 162 182 
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genotypes 192/192 (mean decline – 1.85 nmol/l, P = 0.002), 
190/192 (mean decline – 4.64 nmol/l, P = 0.008) and in sub-
jects from the remaining group (mean decline – 3.58 nmol/l, 
P < 0.0001), but not in 192/194 and 192/196. 
DISCUSSION 
 This explorative study describes the distribution of the 
IGF-I promoter polymorphisms and examines the relation-
ship between IGF-I promoter genotype and IGF-I level. The 
repeat lengths found previously vary from a minimum of 10 
repeats to a maximum of 23 repeats [6,12]. As a conse-
quence it is theoretically possible to find 14 different alleles. 
In our study sample consisting of Caucausion subjects seven 
different alleles were present. Mainly the 192bp and 194bp 
alleles were present in our sample. The allele frequency of 
the 192bp allele was 63.9%, which corresponds to the allele 
frequency reported in other Caucasian populations, estimated 
to be between 59% [14] and 70% [20]. In line with former 
reports, the allele frequency we found for the 194bp allele 
was 20.2% [9,14,20]. Although the occurrence of the other 
genotypes has been determined in other studies, they are 
most often referred to as ‘others’. In agreement with findings 
of studies reported previously, homozygosity for 192bp had 
highest prevalence 39.8%) [9,14,23,32] and heterozygotes 
192/194 were observed in 29.3% [14]. We, however, have 
described the occurrence and the relationships with IGF-I 
levels of the other genotypes more specifically. In the pre-
sent study also a remaining group was included in the analy-
ses. As this group consisted of such a heterogeneous variety 
of genotypes with low frequencies, we considered it useless 
to take the results into account and therefore leave these out 
of the discussion.  
 With respect to females, we found significantly higher 
IGF-I levels for the 190/192 group compared to the 192/192, 
the 192/194 and the 192/196 genotypes. In studies that di-
vided subjects into ‘carriers’ and ‘non-carriers’ of the 192bp 
allele, subjects with the 190/192 genotype were in the same 
group as subjects with 192/192 and 192/196 genotypes 
[20,27,33]. As a consequence, the comparison between carri-
ers and non-carriers lacks specificity. In the same way the 
comparison of ‘homozygotes’ vs. ‘heterozygotes and non-
carriers’ in other studies is not specific. Thus, in contrast to 
former studies we were able to show that the IGF-I level of 
the 190/192 genotypes in females was higher than that of 
other genotypes.  
 The mean IGF-I levels found in our study were in the 
normal range (in both men and in women, aged 36 – 40 
years: 11.2 – 35.7 nmol/l (P5-P95); in men and women aged 
41-51 years: 9.7 – 28.8 nmol/l (P5-P95)). Our results suggest 
that heterozygotes 190/192 in females had higher IGF-I lev-
els than others. Therefore, differences in bone mineral den-
sity, body composition, lipid profile and brain functioning 
are likely to differ between genotypes, and between men and 
women. Moreover, several studies have investigated the rela-
tionship between the IGF-I promoter polymorphism and risk 
of specific disorders, e.g. breast cancer, bone mineral den-
sity, colorectal cancer, hereditary non-polyposis colorectal 
cancer, prostate cancer, type 2 diabetes, cardiovascular dis-
ease and polycystic ovary syndrome [7,9,12]. Most of these 
studies focused on the 192bp allele. Considering the results 
of the present study, it is more revealing to focus in females 
on the 190/192 genotype while examining the effect of the 
IGF-I promoter polymorphism on various disorders.  
 It has been postulated that decreasing levels of IGF-I may 
be partly responsible for effects of aging, as these are similar 
to IGF-I deficiency [2,34-37]. With respect to the expected 
decrease in IGF-I levels from 2000 to 2006 we found a re-
duction in IGF-I levels from 2000 to 2006 with respect to all 
four genotypes when sex was not taken into account. How-
ever, IGF-I decline appeared to be sex-specific as no signifi-
cant decrease was found in males with genotype 190/192 and 
in females with genotypes 192/194 and 192/196. Rietveld et 
al. [23] found an age-related decline in IGF-I levels in ho-
mozygotes 192/192 but not in heterozygotes and non-carriers 
of the 192bp allele. There was no distinction made between 
males and females. With respect to females our results are 
similar, noting that due to infrequent occurrence no non-
carriers of the 192bp allele were evaluated in our study. 
Rietveld et al. suggested that the IGF-I levels in heterozy-
gotes and non-carriers are less growth hormone-dependent 
and more influenced by other factors such as liver function, 
nutrition and insulin levels, and show therefore no decline 
along with the growth hormone levels. In our study growth 
hormone levels were not measured and further studies are 
needed to test this hypothesis. 
Table 2. Mean BMI Values(kg/m
2
) ± SD and Number (and Percentage) of Oral Contraceptive Users within different Genotype 
Groups 
 2000 2006 
Genotype Male  Female  Male  Female  
 BMI BMI OC BMI BMI OC 
192/192 24.2 ± 2.8  23.5 ± 3.7 33 (44) 24.6 ± 2.8 24.2 ± 4.2 25 (33) 
190/192 25.4 ± 3.5  24.2 ± 5.4   5 (42) 25.9 ± 3.4 26.1 ± 8.0   2 (17) 
192/194 25.5 ±  2.5 23.0 ± 3.0 13 (25) 26.0 ± 3.0 23.5 ± 3.1   7 (14) 
192/196 25.2 ± 2.3  23.2 ± 2.9   7 (39) 25.2 ± 3.2 23.8 ± 3.4   2 (11) 
other 24.3 ± 2.7  23.6 ±  2.9   6 (46) 24.4 ± 2.7 24.7 ± 3.1   5 (38) 
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 Our results suggest that IGF-I levels are influenced by 
IGF-I polymorphisms. Yet, the mechanism through which 
the IGF-I polymorphism influences the IGF-I level is still 
unclear. It may affect transcription or it may be in linkage 
disequilibrium with another functional variant. Although 
there are no regulatory elements close to the repeat region, it 
has been shown that CA elements are able to form unusual 
DNA conformations, such as Z-forms, that may modulate 
transcriptional activity [38]. Furthermore, since the replica-
tion fork pauses at the repeats with an increasing repeat 
length, the DNA becomes more unstable and is more prone 
to involve slippage events or doublestrand breaks [12,39].  
 It is important to note that the method used in the present 
study to determine genetic polymorphisms of the IGF-I-gene 
may have introduced errors in the classification of genotype. 
In a small case-control study comparing sizing analysis with 
direct DNA sequencing in analyzing CA repeats in the IGF-I 
gene a substantial discrepancy between the methods in de-
termining homozygous alleles was found. From this ob-
served discrepancy the authors conclude that although DNA 
sizing analysis is the method of choice in analyzing short 
tandem repeat (STR) polymorphisms, laboratory analysis of 
dinucleotide STR may be unreliable in detecting small allelic 
differences [40]. Thus, our study results should be inter-
preted cautiously. 
 In addition, other polymorphisms in the IGF-I gene may 
contribute to IGF-I levels. Recently, data have been pub-
lished on Single Nucleotide Polymorphisms (SNPs) within 
the IGF-I locus, or within evolutionarily conserved non-
coding regions (ECRs) close to the IGF-I locus. Different 
SNPs, significantly associated with IGF-I levels have been 
found: rs35767 [41-43], rs6220 [41,44,45], rs1520220 [44-
46] rs35765 [41], rs5742678, rs5742694 and rs2946834 [44], 
rs7965399 [43] and rs6214, rs5742612, rs5742614, rs5742-
657, rs5742692, and rs3730204 [46]. Others found no sig-
nificant associations between IGF-I tag SNPs and circulating 
Table 3. Mean IGF-I Levels (nmol/l) ± SD in 2000 and in 2006 in Males and Females with different Genotypes 
 2000 2006 
Genotype Male (n) Female (n) Male (n) Female (n) 
192/192 26.84 ± 5.31 (62) 24.29 ± 5.96 (75) 23.17± 4.96 (49)? 22.44 ± 5.70 (66)? 
190/192 24.74 ± 5.42 (7) 29.24 ± 7.57 (12)* 22.63± 5.77 (7) 24.60 ± 7.41 (10)? 
192/194 27.37 ±  6.0  (50) 24.61 ± 5.50 (51) 25.76 ± 5.61 (44)? 23.55 ± 4.70 (41) 
192/196 27.35 ± 3.90 (12) 23.93 ± 3.99 (18) 23.17 ± 4.61 (8)? 23.38 ± 4.05 (15) 
other 25.89 ± 6.0 (31) 28.42 ± 6.92 (26)* 24.94 ± 6.19 (25) 24.84 ± 5.73 (22)? 
All 26.77 ± 5.55 (162) 25.26 ±  6.14(182) 24.33 ± 5.50 (133)? 23.31 ± 5.44 (154)? 
*P ? 0.01 vs female genotypes 192/192, 192/194, 192/196      ? P < 0.03 vs 2000  
 
Fig. (1). Mean IGF-I levels (nmol/l) ± SD in 2000 and in 2006 in females with different genotypes. 
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levels of IGF-I [47]. In this study we have not taken the pos-
sible influence of these polymorphisms on the IGF-I levels 
into account. 
 In conclusion, our population-based 6-year longitudinal 
study with Caucasian men and women studied at average 
ages of 36 and 42 years suggests that a genetic polymor-
phism in the promoter region of the IGF-I gene interacts with 
both sex and age in its IGF-I expression. In the general Cau-
casian population, the presence of the 190/192 genotype in 
females (as observed in 6.6% of women) seems associated 
with higher IGF-I levels. Furthermore, no age-related decline 
of the IGF-I levels was observed in males with genotype 
190/192 and in females with genotypes 192/194 and 
192/196. This may have consequences for tissues and meta-
bolic factors on which IGF-I acts, e.g. for bone, lipids and 
brain. Further studies are needed to clarify the clinical impli-
cations of the observed genotype-related differences in (de-
cline of) IGF-I levels.  
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